From Dr. Pourhassan responding to questions...
Would love to do what our scientists and experts suggest and we'll have a meeting shortly on that...
Patent Protection: have over 57 patents filed and protected....
Will let Dr. Fauci and Gilead speak about Gilead... they weren't given any special privileges... we were given special privileges
Talking to UK, Italy and Iran as well as other countries...
Will have 600K doses for 300K patients for two weeks
Woking on approval to bring Virologix to market... working on it all for all
indications... (own comment: was asked for timing but didn't say anything more specific)
Dr. Patterson:
Using diagnostics to show efficacy and safety ... and have clinical trials to show exactly what's proceeding, that's the elegance of how we're doing this as a group and seeing it on a day-to-day basis telling us we're on the right track... there's two levels o clinical significance... have to let the FDA do their things and we're looking at the data on how the drug works on Covid and saying the drug is doing what it's supposed to be doing... have great confidence about a positive outcome.
Pourhassan: got 15 for severe trial and maybe can get in there when we have 50...
Don't expect any major adverse effect based on HIV done already...
Patterson: nothing on the market that can say no renal, liver or serious adverse side effects on a patient... (Leronlimab can say that)
Both other meds from Genentech and ___ are piecemeal... these other approaches are just treating one aspect of the spectrum of alterations in Covid-19... at the end of the day, piecemeal approaches are not going to be the solution... in fact Dr. Fauci said the other day there needs to be an anti-inflamatory as well which sets up Leronlimab perfectly.
Pourhassan:
Board members are preparing and meeting to set up for eventual sales
Condition No. Patients Results
Very critically ill- 11- 4 were saved
Criticaly ill- 11- 10 either extubated
or improving
Severely ill- 17- No results on 2,
13 out of 15 either
discharged or improving
Mid-to-Moderate- 0- N/A
Would love to do what our scientists and experts suggest and we'll have a meeting shortly on that...
Patent Protection: have over 57 patents filed and protected....
Will let Dr. Fauci and Gilead speak about Gilead... they weren't given any special privileges... we were given special privileges
Talking to UK, Italy and Iran as well as other countries...
Will have 600K doses for 300K patients for two weeks
Woking on approval to bring Virologix to market... working on it all for all
indications... (own comment: was asked for timing but didn't say anything more specific)
Dr. Patterson:
Using diagnostics to show efficacy and safety ... and have clinical trials to show exactly what's proceeding, that's the elegance of how we're doing this as a group and seeing it on a day-to-day basis telling us we're on the right track... there's two levels o clinical significance... have to let the FDA do their things and we're looking at the data on how the drug works on Covid and saying the drug is doing what it's supposed to be doing... have great confidence about a positive outcome.
Pourhassan: got 15 for severe trial and maybe can get in there when we have 50...
Don't expect any major adverse effect based on HIV done already...
Patterson: nothing on the market that can say no renal, liver or serious adverse side effects on a patient... (Leronlimab can say that)
Both other meds from Genentech and ___ are piecemeal... these other approaches are just treating one aspect of the spectrum of alterations in Covid-19... at the end of the day, piecemeal approaches are not going to be the solution... in fact Dr. Fauci said the other day there needs to be an anti-inflamatory as well which sets up Leronlimab perfectly.
Pourhassan:
Board members are preparing and meeting to set up for eventual sales
Condition No. Patients Results
Very critically ill- 11- 4 were saved
Criticaly ill- 11- 10 either extubated
or improving
Severely ill- 17- No results on 2,
13 out of 15 either
discharged or improving
Mid-to-Moderate- 0- N/A
3
